Selective sodium-glucose cotransporter-2 inhibitors in the improvement of hemoglobin and hematocrit in patients with type 2 diabetes mellitus: a network meta-analysis

Abstract

Objective:

To compare the effects of different selective sodium-glucose cotransporter-2 inhibitors (SGLT2i) on hemoglobin and hematocrit in patients with type 2 diabetes mellitus (T2DM) with a network meta-analysis (NMA).

Methods:

Randomized controlled trials (RCTs) on SGLT2i for patients with T2DM were searched in PubMed, Embase, Cochrane Library, and Web of Science from inception of these databases to July 1, 2023. The risk of bias (RoB) tool was used to evaluate the quality of the included studies, and R software was adopted for data analysis.

Results:

Twenty-two articles were included, involving a total of 14,001 T2DM patients. SGLT2i included empagliflozin, dapagliflozin, and canagliflozin. The NMA results showed that compared with placebo, canagliflozin 100mg, canagliflozin 300mg, dapagliflozin 10mg, dapagliflozin 2mg, dapagliflozin 50mg, dapagliflozin 5mg, empagliflozin 25mg, and dapagliflozin 20mg increased hematocrit in patients with T2DM, while canagliflozin 100mg, canagliflozin 200mg, canagliflozin 300mg increased hemoglobin in patients with T2DM. In addition, the NMA results indicated that canagliflozin 100mg had the best effect on the improvement of hematocrit, and canagliflozin 200mg had the best effect on the improvement of hemoglobin.

Conclusion:

Based on the existing studies, we concluded that SGLT2i could increase hematocrit and hemoglobin levels in patients with T2DM, and canagliflozin 100mg had the best effect on the improvement of hematocrit, while canagliflozin 200mg had the best effect on the improvement of hemoglobin.

Systematic review registration:

https://www.crd.york.ac.uk/PROSPERO/#loginpage, identifier PROSPERO (CRD42023477103).

1 Introduction

In recent decades, the prevalence of type 2 diabetes mellitus (T2DM) has increased rapidly. According to the prediction of the International Diabetes Federation (IDF), there will be over 700 million T2DM cases by 2045, making the disease a significant “killer” that threatens human health in the 21st century (1, 2). The global prevalence of diabetes was estimated to be 10.5% in adults aged 20-79 in 2021 (536.6 million cases). This number is predicted to rise according to a diabetes mellitus (DM) prediction model of IDF (3). In addition, anemia is prevalent in patients with T2DM, with approximately 1/4 of T2DM patients being anemic (4). Early evidence suggests that the development of anemia in patients with DM is usually related to nephropathy, with erythropoietin (EPO) deficiency or iron deficiency being the main causes (5, 6). Anemia is an important cause of irreversible damage to heart, brain, kidney, and other important organs in patients with T2DM, as well as an important cause of an increased mortality rate. It is an independent risk factor affecting the prognosis in patients with T2DM (7). Therefore, how the anemia status of T2DM patients can be improved has become a hot topic (8).

At present, a comprehensive management model is adopted for the treatment of T2DM, involving lowering blood glucose, lowering blood pressure, regulating blood lipids, anti-platelet, weight control and improving lifestyle. Despite a comprehensive management, the blood glucose in some patients is not well controlled (9). Sodium-glucose cotransporter-2 inhibitor (SGLT2i) is a hot topic in recent research, mainly focusing on the selective SGLT2i. SGLT2 is a glucose transporter in the renal proximal tubule (10). In recent years, it has been found that SGLT2 can ensure the balance between filtration and renal reabsorption of glucose, without urinary glucose excretion. A large number of studies have pointed out that by inhibiting SGLT2, the reabsorption of glucose in the kidney can be reduced, increasing the urinary glucose excretion. In this way, the blood glucose level can be reduced (11, 12). At present, SGLT2i mainly includes empagliflozin, dapagliflozin, and canagliflozin. When SGLT2i is used to treat diabetes, it can reduce blood glucose separately, without relying on insulin. At the same time, it can effectively reduce the weight of patients, reduce the blood pressure level, and reduce urinary protein, helping patients with DM reach the blood control goal and protect kidney functions effectively (13, 14). A previous meta-analysis (15) indicated that SGLT2i improved hemoglobin and hematocrit in patients with T2DM. However, the effect of SGLT2i on the improvement of hemoglobin and hematocrit in patients with T2DM remains controversial. Some studies indicate that it can increase hemoglobin and hematocrit in patients with T2DM, while other studies show the opposite results (16, 17). In addition, there is a lack of head-to-head comparison of several types of SGLT2i, and the recommended dosage also remains controversial (18). Therefore, a network meta-analysis (NMA) was performed in this study to address the above controversies and provide new options for the treatment of patients with T2DM.

2 Methods

2.1 Meta registration

This meta-analysis was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. The protocol for the study has been registered with PROSPERO (registration number: CRD42023477103).

2.2 Literature search

Cochrane, PubMed, Embase, and Web of Science were searched for randomized controlled trials (RCTs) on the effects of SGLT2i on the improvement of hemoglobin and hematocrit in patients with T2DM from the inception of these databases up to July 1, 2023. A combination of subject terms and free words were used for literature search, including type 2 diabetes mellitus, sodium-glucose cotransporter-2, empagliflozin, dapagliflozin, canagliflozin, hemoglobin, and hematocrit. The detailed search strategy is shown in Supplementary Material 1.

2.3 Eligibility criteria

Inclusion criteria: The participants were adults who met the diagnostic criteria (19) of T2DM (HbA1c levels ≥ 7.0% to ≤10.0%) in the included studies. The intervention was SGLT2i (empagliflozin, dapagliflozin, canagliflozin), and the control intervention was placebo. The primary outcome was hematocrit, and the secondary outcome was hemoglobin. The study type was an RCT.

Exclusion criteria: duplicate publications, animal studies, case reports, conference abstracts, reviews, studies with no available full texts.

2.4 Data extraction

Two independent authors performed a rigorous screening of literature based on the pre-defined inclusion and exclusion criteria. In case of any disagreement, a consensus was reached through discussion between the two authors or consultation with a third researcher. The following key data were extracted from the included studies: first author, year of publication, country, sample size, gender, age, interventions, and outcome measures.

2.5 Quality assessment

The risk of bias was assessed using version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2) (20) from five major domains: bias arising from the randomization process, bias due to deviations from intended interventions, bias due to missing outcome data, bias in the measurement of the outcome, and bias in the selection of the reported results. The judgements can be “low risk of bias”, “some concerns” and “high risk of bias”. The results of the study were checked by the two researchers and disagreements, if any, were discussed between the two researchers, or addressed through consultation with a third researcher.

2.6 Quality rating by GRADE

The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was adopted to assess the methodological quality of the evidence to determine the quality of the results (21). We considered five domains that may reduce the quality of evidence, including study limitations, inconsistency, indirectness, imprecision or wide confidence intervals, and publication bias. In addition, we reviewed factors that could reduce the quality of evidence, namely effect size, possible confounders, and dose-effect relationship. A comprehensive description of the quality of the evidence for each outcome is provided in Table 1.

2.7 Data analysis

R4.3.2 software (R Foundation for Statistical Computing) was used to conduct Bayesian NMA of multi-group trials using a Markov chain Monte Carlo method with vague prior distribution and a random effects model (22)to obtain the best pooled estimates and probabilities for each treatment regimen. The trajectory plot and Brooks-Gelman-Rubin plot were plotted to evaluate the convergence of the model, and the continuous outcomes were expressed as posterior mean difference (MD) and its 95% confidence interval (CI). The surface under the cumulative ranking curve (SUCRA) was calculated to estimate the probability of each treatment as the optimal intervention. The network, “networkplot” and “sencode” packages in STATA 15.0 were used to draw network diagram and funnel plots. In the network diagram, each circle represents a drug, and the lines represent existing comparisons. The size of the circle is positively related to the number of included patients. The “ggplot2” package was used to create the cumulative probability plot, and a P-value < 0.05 was statistically significant.

3 Results

3.1 Literature screening process and results

A total of 2,966 articles were obtained through the preliminary search of databases, and 577 duplicates were removed. After reading the titles and abstracts, we excluded 2,406 articles, and 11 articles were eliminated by reading the full texts. A total of 22 (23–44) articles were eventually included for analysis (Figure 1).

Figure 1

3.2 Characteristics of literature and risk of bias assessment

The 22 articles involved 14,001 T2DM patients, and the mean age was 50-64 years. The SGLT2i covered empagliflozin, dapagliflozin, and canagliflozin, with a dose range of 1 to 300 mg. The specific characteristics of literature are shown in Table 2. All the included studies clearly described the blinding method, and the high risk mainly arose from deviations from intended interventions. Figures 2, 3 show the risk of bias assessment of the included studies.

Figure 2

Figure 3

3.3 Results of NMA

3.3.1 Hematocrit

Fifteen of the included (23, 25, 26, 28–31, 33, 34, 38, 45) studies reported hematocrit, as shown in Figure 4, and a closed loop was observed in the network diagram (Figure 4A). Therefore, the local inconsistency test was performed. The results suggested no difference in the direct, indirect and network comparisons between dapagliflozin 10 mg and dapagliflozin 1 mg, dapagliflozin 10mg and dapagliflozin 2mg, as well as between dapagliflozin 10mg and dapagliflozin 5mg, as shown in Supplementary Figure 1; Supplementary Material 2. Compared with placebo, canagliflozin 100mg [MD=6.11,95%CI(2.16, 10.1)], canagliflozin 300mg [MD=4.91,95%CI(1.05, 8.76)], dapagliflozin 10mg [MD=2.03,95%CI(1.06,3.01)], dapagliflozin 2mg [MD=1.77, 95%CI(0.732, 2.80)], dapagliflozin 50mg [MD=2.89, 95%CI(0.513, 5.29)], dapagliflozin 5mg [MD=1.74, 95%CI(0.772,2.78)], empagliflozin 25mg [MD=1.97,95%CI(0.166,3.80)], dapagliflozin 20 mg [MD = 2.6, 95% CI (0.245, 4.96)] increased hematocrit in patients with T2DM (Figure 4C), and the effect of canagliflozin 100 mg was better than that of dapagliflozin 10mg, dapagliflozin 1mg, dapagliflozin 2mg, dapagliflozin 5mg, and empagliflozin 10mg (Supplementary Table 1 in Supplementary Material 2). The SUCRA of canagliflozin 100mg was the largest (91%), followed by canagliflozin 300mg (86%) and dapagliflozin 50mg (69%), and the SUCRA of placebo was the smallest (5%) (Figure 4B; Table 3).

Figure 4

3.3.2 Hemoglobin

Eleven of the included (23, 24, 27, 31, 33, 36, 37, 39, 41, 43, 44) articles reported hemoglobin, as shown in Figure 5. A closed loop was observed in the network diagram (Figure 5A), but the local inconsistency test was not performed due to the limited number of relevant studies. Compared with placebo, canagliflozin 100mg [MD=4.86,95%CI (3.93,5.83)], canagliflozin 200mg [MD=5.15,95%CI (3.64,6.69)], canagliflozin 300mg [MD = 4.27, 95% CI (3.19, 5.53)] increased hemoglobin in patients with T2DM (Figure 5C), but the effects of canagliflozin 100mg, canagliflozin 200mg, and canagliflozin 300mg showed no significant difference (Supplementary Table 1 in Supplementary Material 2). The SUCRA of canagliflozin 200mg was the largest (92%), followed by canagliflozin 100mg (87%) and canagliflozin 300mg (71%), and the SUCRA of placebo was the smallest (4%) (Figure 5B; Table 3).

Figure 5

3.3.3 Assessment of publication bias

We used funnel plots to evaluate the publication bias for hematocrit and hemoglobin, and the results suggested a high possibility of publication bias for hematocrit and hemoglobin (Supplementary Figures 2, 3 in Supplementary Material 2).

3.3.4 Sensitivity analysis

Sensitivity analysis was conducted on hemoglobin and hematocrit. The analysis results are shown in Figures S4–6 and Figures S7–14 in Supplementary Material 2, respectively.

4 Discussion

To our knowledge, this study is the first to evaluate the effects of different types and dosages of SGLT2i on the improvement of hematocrit and hemoglobin in patients with T2DM. A previous meta-analysis (15) indicated that SGLT2i increased hemoglobin and hematocrit levels compared with the control group, but it did not explore the dosage of SGLT2i in-depth and lacked a direct comparison between different interventions. We evaluated the effects of different dosages of SGLT2i, and this was an innovation of our research.

According to this study, canagliflozin 100mg [MD=6.11,95%CI (2.16, 10.1)] was most effective in increasing hematocrit, followed by canagliflozin 300mg [MD=4.91,95%CI (1.05, 8.76)] and dapagliflozin 50mg [MD=2.89, 95%CI (0.513, 5.29)], while canagliflozin 200mg [MD=5.15,95%CI (3.64,6.69)] was most effective in increasing hemoglobin, followed by canagliflozin 100mg [MD=4.86,95%CI (3.93,5.83)] and dapagliflozin 300mg [MD = 4.27, 95% CI (3.19, 5.53)]. The fact that SGLT2i increased hemoglobin and hematocrit could be partly explained by the unique role of SGLT2i in glucose excretion via the kidney, contributing to osmotic diuresis and leading to a significant increase in hemoglobin and hematocrit, which would help to lower blood pressure and relieve heart failure (46). Some studies have speculated that SGLT2i reduces ATP consumption through the Na+/K+ pump and alleviates the metabolic stress of renal proximal tubular epithelial cells (PTECs), thereby reducing hypoxia (47, 48) in the microenvironment around proximal renal tubules. This may allow myofibroblasts in the mesenchyme to reverse to some extent to erythropoietin-producing fibroblasts, enhancing the hematopoiesis and elevating hematocrit (49). Some other studies suggest that SGLT2i can prevent damage to renal mesenchymal cells by reducing the activity of the SGLT2 pathway on proximal tubular cells, and this will maintain an adequate erythropoietin level, and subsequently increase hemoglobin and hematocrit levels (50, 51). It has also been found in other studies that the increase of hematocrit may be closely related to the correction of sympathetic hyperfunction, leading to the reduction of cardiovascular mortality and the risk of hospitalization due to heart failure (52).

According to this study, canagliflozin showed the best effect, and this may be due to its dual inhibition of SGLT1 and SGLT2. Since SGLT1 is mainly expressed in the intestine, canagliflozin may change the intestinal environment or flora structure through the inhibition of intestinal SGLT1. Polidori et al. (53) found that canagliflozin decreased postprandial blood glucose and insulin by increasing urinary glucose excretion through the inhibition of renal SGLT2 and by delaying the use of oral glucose, and this might be related to the inhibition of intestinal SGLT1. Intestinal bacteria affect the iron absorption of the host, and iron intake will affect the virulence of bacteria. The host-intestinal bacteria interactions affect the systemic iron level and iron storage in different tissues and may therefore have an impact on hemoglobin or hematocrit (54). Although this study explored the differences between various doses, the top interventions showed no significant differences in effects as shown in the league table. This research provided an option for T2DM patients with anemia, but more research is needed to validate our findings on the choice of doses.

All the included studies clearly state the use of random method, and they are therefore of higher quality, indicating that our conclusions are reliable. In terms of hemoglobin, a low quality was rated, possibly due to the small number of included studies, and this may reduce the credibility of our conclusion. For hematocrit, a moderate quality was rated, and this may be caused by heterogeneity. The potential heterogeneity among studies may be due to the inconsistency of the study population or the inconsistency of the dose of the drugs used, but the potential heterogeneity did not affect our conclusions.

Although this study confirmed that SGLT2i could increase hematocrit and hemoglobin in patients with T2DM, the following limitations should be noted. First, hematocrit and hemoglobin were not analyzed as the primary outcomes in the included studies. Second, there was a greater heterogeneity among studies due to the different time for statistics of outcomes. Third, there was a greater heterogeneity among the treatment methods for the included patients.

5 Conclusion

Based on the existing studies, SGLT2i can improve hematocrit and hemoglobin in patients with T2DM, and canagliflozin 100mg is most effective in elevating hematocrit, while canagliflozin 200mg is most effective in elevating hemoglobin.

References

• 1

  FaizanMSarkarASinghMP. Type 2 diabetes mellitus augments Parkinson’s disease risk or the other way around: Facts, challenges and future possibilities. Ageing Res Rev (2022) 81:101727. doi: 10.1016/j.arr.2022.101727

  • CrossRef
  • Google Scholar
  • View reference in article

• 2

  NauckMAWefersJMeierJJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol (2021) 9(8):525–44. doi: 10.1016/S2213-8587(21)00113-3

  • CrossRef
  • Google Scholar
  • View reference in article

• 3

  SunHSaeediPKarurangaSPinkepankMOgurtsovaKDuncanBBet al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract (2022) 183:109119. doi: 10.1016/j.diabres.2021.109119

  • CrossRef
  • Google Scholar
  • View reference in article

• 4

  OlumRBongominFKaggwaMMAndia-BiraroIBalukuJB. Anemia in diabetes mellitus in Africa: A systematic review and meta-analysis. Diabetes Metab Syndr (2021) 15(5):102260. doi: 10.1016/j.dsx.2021.102260

  • CrossRef
  • Google Scholar
  • View reference in article

• 5

  Al-KhourySAfzaliBShahNThomasSGusbeth-TatomirPGoldsmithDet al. Diabetes, kidney disease and anaemia: time to tackle a troublesome triad? Int J Clin Pract (2007) 61(2):281–9. doi: 10.1111/j.1742-1241.2006.01259.x

  • CrossRef
  • Google Scholar
  • View reference in article

• 6

  KamoiKTakedaKHashimotoKTanakaROkuyamaS. Identifying risk factors for clinically significant diabetic macula edema in patients with type 2 diabetes mellitus. Curr Diabetes Rev (2013) 9(3):209–17. doi: 10.2174/1573399811309030002

  • CrossRef
  • Google Scholar
  • View reference in article

• 7

  RitzE. Managing anaemia and diabetes: a future challenge for nephrologists. Nephrol Dial Transplant (2005) 20 Suppl 6:vi21–5. doi: 10.1093/ndt/gfh1093

  • CrossRef
  • Google Scholar
  • View reference in article

• 8

  PraveenMJainNRaizadaNSharmaSNarangSMadhuSV. Anaemia in patients with type 2 diabetes mellitus without nephropathy is related to iron deficiency. Diabetes Metab Syndr (2020) 14(6):1837–40. doi: 10.1016/j.dsx.2020.09.020

  • CrossRef
  • Google Scholar
  • View reference in article

• 9

  FergusonDFinckBN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol (2021) 17(8):484–95. doi: 10.1038/s41574-021-00507-z

  • CrossRef
  • Google Scholar
  • View reference in article

• 10

  PackerM. Potential interactions when prescribing SGLT2 inhibitors and intravenous iron in combination in heart failure. JACC Heart Fail (2023) 11(1):106–14. doi: 10.1016/j.jchf.2022.10.004

  • CrossRef
  • Google Scholar
  • View reference in article

• 11

  LiuZMaXIlyasIZhengXLuoSLittlePJet al. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics. Theranostics (2021) 11(9):4502–15. doi: 10.7150/thno.54498

  • CrossRef
  • Google Scholar
  • View reference in article

• 12

  PackerM. SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism. Nat Rev Cardiol (2023) 20(7):443–62. doi: 10.1038/s41569-022-00824-4

  • CrossRef
  • Google Scholar
  • View reference in article

• 13

  AndersHJHuberTBIsermannBSchifferM. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. (2018) 14(6):361–77. doi: 10.1038/s41581-018-0001-y

  • CrossRef
  • Google Scholar
  • View reference in article

• 14

  FerranniniESoliniA. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol (2012) 8(8):495–502. doi: 10.1038/nrendo.2011.243

  • CrossRef
  • Google Scholar
  • View reference in article

• 15

  KanbayMTapoiLUrecheCTanrioverCCevikEDemirayAet al. Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis. Int Urol Nephrol. (2022) 54(4):827–41. doi: 10.1007/s11255-021-02943-2

  • CrossRef
  • Google Scholar
  • View reference in article

• 16

  KaplanAAbidiEEl-YazbiAEidABoozGWZoueinFA. Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. Heart Fail Rev (2018) 23(3):419–37. doi: 10.1007/s10741-017-9665-9

  • CrossRef
  • Google Scholar
  • View reference in article

• 17

  FonsecaVAFerranniniEWildingJPWilpshaarWDhanjalPBallGet al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications. (2013) 27(3):268–73. doi: 10.1016/j.jdiacomp.2012.11.005

  • CrossRef
  • Google Scholar
  • View reference in article

• 18

  ScheenAJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol (2013) 9(5):529–50. doi: 10.1517/17425255.2013.777428

  • CrossRef
  • Google Scholar
  • View reference in article

• 19

  KrugerDFBoucherJLBanerjiMA. Utilizing current diagnostic criteria and treatment algorithms for managing type 2 diabetes mellitus. Postgrad Med (2011) 123(4):54–62. doi: 10.3810/pgm.2011.07.2304

  • CrossRef
  • Google Scholar
  • View reference in article

• 20

  Higgins JPTSJPageMJet al. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0) (2016). Available at: https://wwwriskofbiasinfo/welcome/rob-2-0-tool/archive-rob-2-0-2016.

  • Google Scholar
  • View reference in article

• 21

  AtkinsDBestDBrissPAEcclesMFalck-YtterYFlottorpSet al. Grading quality of evidence and strength of recommendations. Bmj (2004) 328(7454):1490. doi: 10.1136/bmj.328.7454.1490

  • CrossRef
  • Google Scholar
  • View reference in article

• 22

  JansenJPCrawfordBBergmanGStamW. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health (2008) 11(5):956–64. doi: 10.1111/j.1524-4733.2008.00347.x

  • CrossRef
  • Google Scholar
  • View reference in article

• 23

  AamirAHRajaUYQureshiFMAsgharAMaharSAAhmedIet al. Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial. BMC Endocr Disord (2022) 22(1):295. doi: 10.1186/s12902-022-01213-1

  • CrossRef
  • Google Scholar
  • View reference in article

• 24

  AndersenCFOmarMGlenthojAEl FassiDMollerHJKurtzhalsJALet al. Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial. Eur J Heart Failure. (2023) 25(2):226–34. doi: 10.1002/ejhf.2735

  • CrossRef
  • Google Scholar
  • View reference in article

• 25

  BaileyCJGrossJLPietersABastienAListJF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet (2010) 375(9733):2223–33. doi: 10.1016/S0140-6736(10)60407-2

  • CrossRef
  • Google Scholar
  • View reference in article

• 26

  BaileyCJIqbalNT’JoenCListJF. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab (2012) 14(10):951–9. doi: 10.1111/j.1463-1326.2012.01659.x

  • CrossRef
  • Google Scholar
  • View reference in article

• 27

  BodeBStenlöfKSullivanDFungAUsiskinK. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). (2013) 41(2):72–84. doi: 10.3810/hp.2013.04.1020

  • CrossRef
  • Google Scholar
  • View reference in article

• 28

  BolinderJLjunggrenÖKullbergJJohanssonLWildingJLangkildeAMet al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab (2012) 97(3):1020–31. doi: 10.1210/jc.2011-2260

  • CrossRef
  • Google Scholar
  • View reference in article

• 29

  FerranniniERamosSJSalsaliATangWListJF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care (2010) 33(10):2217–24. doi: 10.2337/dc10-0612

  • CrossRef
  • Google Scholar
  • View reference in article

• 30

  GaboritBAncelPAbdullahAEMauriceFAbdesselamICalenAet al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovasc diabetology. (2021) 20(1):57. doi: 10.1186/s12933-021-01237-2

  • CrossRef
  • Google Scholar
  • View reference in article

• 31

  GhanimHAbuayshehSHejnaJGreenKBatraMMakdissiAet al. Dapagliflozin suppresses hepcidin and increases erythropoiesis. J Clin Endocrinol Metab (2020) 105(4):E1056–E63. doi: 10.1210/clinem/dgaa057

  • CrossRef
  • Google Scholar
  • View reference in article

• 32

  HoshikaYKubotaYMozawaKTaraSTokitaYYodogawaKet al. Effect of empagliflozin versus placebo on plasma volume status in patients with acute myocardial infarction and type 2 diabetes mellitus. Diabetes Ther (2021) 12(8):2241–8. doi: 10.1007/s13300-021-01103-0

  • CrossRef
  • Google Scholar
  • View reference in article

• 33

  JensenJOmarMKistorpCTuxenCGustafssonIKøberLet al. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. Lancet Diabetes endocrinology. (2021) 9(2):106–16. doi: 10.1016/S2213-8587(20)30382-X

  • CrossRef
  • Google Scholar
  • View reference in article

• 34

  KakuKInoueSMatsuokaOKiyosueAAzumaHHayashiNet al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab (2013) 15(5):432–40. doi: 10.1111/dom.12047

  • CrossRef
  • Google Scholar
  • View reference in article

• 35

  KovacsCSSeshiahVSwallowRJonesRRattundeHWoerleHJet al. Empagliflozin impr`oves glycaemic an d weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: A 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab (2014) 16(2):147–58. doi: 10.1111/dom.12188

  • CrossRef
  • Google Scholar
  • View reference in article

• 36

  Lavalle-GonzálezFJJanuszewiczADavidsonJTongCQiuRCanovatchelWet al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia (2013) 56(12):2582–92. doi: 10.1007/s00125-013-3039-1

  • CrossRef
  • Google Scholar
  • View reference in article

• 37

  LeeSHMinKWLeeBWJeongIKYooSJKwonHSet al. Effect of dapagliflozin as an add-on therapy to insulin on the glycemic variability in subjects with type 2 diabetes mellitus (DIVE): A multicenter, placebo-controlled, double-blind, randomized study. . Diabetes Metab J (2021) 45(3):339–48. doi: 10.4093/dmj.2019.0203

  • CrossRef
  • Google Scholar
  • View reference in article

• 38

  ListJFWooVMoralesETangWFiedorekFT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care (2009) 32(4):650–7. doi: 10.2337/dc08-1863

  • CrossRef
  • Google Scholar
  • View reference in article

• 39

  StenlöfKCefaluWTKimKAAlbaMUsiskinKTongCet al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab (2013) 15(4):372–82. doi: 10.1111/dom.12054

  • CrossRef
  • Google Scholar
  • View reference in article

• 40

  StrojekKYoonKHHrubaVElzeMLangkildeAMParikhS. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab (2011) 13(10):928–38. doi: 10.1111/j.1463-1326.2011.01434.x

  • CrossRef
  • Google Scholar
  • View reference in article

• 41

  ThieleKRauMHartmannNUKMollmannJJankowskiJBohmMet al. Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study. Diabetes Obes Metab (2021) 23(12):2814–8. doi: 10.1111/dom.14517

  • CrossRef
  • Google Scholar
  • View reference in article

• 42

  WildingJPWooVSolerNGPahorASuggJRohwedderKet al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med (2012) 156(6):405–15. doi: 10.7326/0003-4819-156-6-201203200-00003

  • CrossRef
  • Google Scholar
  • View reference in article

• 43

  YaleJFBakrisGCariouBYueDDavid-NetoEXiLet al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab (2013) 15(5):463–73. doi: 10.1111/dom.12090

  • CrossRef
  • Google Scholar
  • View reference in article

• 44

  ZinmanBWannerCLachinJMFitchettDBluhmkiEHantelSet al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl J Med (2015) 373(22):2117–28. doi: 10.1056/NEJMoa1504720

  • CrossRef
  • Google Scholar
  • View reference in article

• 45

  KovacsCSSeshiahVSwallowRJonesRRattundeHWoerleHJet al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: A 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab (2014) 16(2):147–58. doi: 10.1111/dom.12188

  • CrossRef
  • Google Scholar
  • View reference in article

• 46

  DobbinsRLO’Connor-SemmesRKapurAKapitzaCGolorGMikoshibaIet al. Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab (2012) 14(1):15–22. doi: 10.1111/j.1463-1326.2011.01462.x

  • CrossRef
  • Google Scholar
  • View reference in article

• 47

  EkanayakePMudaliarS. Increase in hematocrit with SGLT-2 inhibitors - Hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia? Diabetes Metab Syndr (2023) 17(2):102702. doi: 10.1016/j.dsx.2022.102702

  • CrossRef
  • Google Scholar
  • View reference in article

• 48

  PackerM. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion. Cardiovasc Diabetol (2019) 18(1):129. doi: 10.1186/s12933-019-0938-6

  • CrossRef
  • Google Scholar
  • View reference in article

• 49

  SanoMGotoS. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation (2019) 139(17):1985–7. doi: 10.1161/CIRCULATIONAHA.118.038881

  • CrossRef
  • Google Scholar

• 50

  MiyataKNLoCSZhaoSZhaoXPChenierIYamashitaMet al. Deletion of heterogeneous nuclear ribonucleoprotein F in renal tubules downregulates SGLT2 expression and attenuates hyperfiltration and kidney injury in a mouse model of diabetes. Diabetologia (2021) 64(11):2589–601. doi: 10.1007/s00125-021-05538-9

  • CrossRef
  • Google Scholar

• 51

  ZhaoSLoCSMiyataKNGhoshAZhaoXPChenierIet al. Overexpression of nrf2 in renal proximal tubular cells stimulates sodium-glucose cotransporter 2 expression and exacerbates dysglycemia and kidney injury in diabetic mice. Diabetes (2021) 70(6):1388–403. doi: 10.2337/db20-1126

  • CrossRef
  • Google Scholar

• 52

  CowieMRFisherM. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol (2020) 17(12):761–72. doi: 10.1038/s41569-020-0406-8

  • CrossRef
  • Google Scholar

• 53

  PolidoriDShaSMudaliarSCiaraldiTPGhoshAVaccaroNet al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care (2013) 36(8):2154–61. doi: 10.2337/dc12-2391

  • CrossRef
  • Google Scholar

• 54

  Mayneris-PerxachsJMoreno-NavarreteJMFernández-RealJM. The role of iron in host-microbiota crosstalk and its effects on systemic glucose metabolism. Nat Rev Endocrinol (2022) 18(11):683–98. doi: 10.1038/s41574-022-00721-3

  • CrossRef
  • Google Scholar